Alterity Therapeutics has recently announced the the Michael J. Fox Foundation will be funding a dose optimization trial for ATH434. According to BioSpace, this grant is the second from the…
In early January 2021, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that its New Drug Application (NDA) and supplemental NDA for Myrbetriq (mirabegron) received Priority Review status from the…
According to Parkinson's News Today, the first patient has been dosed in a Phase 1 clinical trial run by IMAC Holdings. The clinical trial is designed to evaluate mesenchymal…
Would you ever think that Alzheimer's disease and one's sense of smell could be related? According to Medical XPress, researchers from the University of Otago in New Zealand are currently…
Currently, there are a host of health-related issues associated with diabetes. One specific health problem, which currently represents an unmet need, is pain associated with diabetic peripheral neuropathy. According to…
In a press release by the Parkinson’s Foundation, the non-profit has announced an exciting collaboration with Sanofi, the global pharmaceutical company, which will dedicated $1 million to the nonprofit to…
Prevail Therapeutics, a company that focuses on developing gene therapies for neurodegenerative diseases, has announced that a composition of matter patent has been issued for PR001. This therapy is intended…
Each year, thousands lose their vision to dominant optic atrophy (DOA), an inherited disease that negatively impacts the optic nerves. However, researchers and scientists from Trinity College Dublin may have…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
